SEASONS BIOTECHNOLOGY (TAIZHOU) CO LTD

Main research purpose: According to the relevant provisions of bioequivalence test, BUFFERIN Combination Tab. A81 (specification: each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, 11 mg aluminum glycolate) with Lion Corporation as the licensee was selected as the reference preparation. The test preparation BUFFERIN Combination Tab. A81 (specification: each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, 11 mg aluminum glycolate) with Puji Biotechnology (Taizhou) Co., Ltd. as the licensee and Lepu Pharmaceutical Technology Co., Ltd. as the production agent was conducted on the fasting and fed human bioequivalence test. The absorption rate and degree of the drug in the test preparation were compared with the reference preparation to see if they were within the acceptable range, and the bioequivalence of the two preparations under fasting and fed conditions was evaluated. Secondary study objective: To observe the safety of oral administration of the test preparation aluminum magnesium aspirin tablets (II) (specification: each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, 11 mg aluminum glycolate) and the reference preparation aluminum magnesium aspirin tablets (II) (trade name: BUFFERIN Combination Tab. A81, specification: each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, 11 mg aluminum glycolate) to healthy subjects.